Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
Tweet Send to a Friend
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
